Cargando…
Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients
The COVID-19 global pandemic has caused about 4,30 Mln deaths. Recently the first vaccines have been licensed, representing the most powerful weapon available to stop the pandemic. The COVID-19 viral infection in the most severe cases can cause severe lung lesions with the presence of fibrotic tissue...
Autores principales: | Vitiello, Antonio, Ferrara, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444447/ https://www.ncbi.nlm.nih.gov/pubmed/34870154 http://dx.doi.org/10.1016/j.crphar.2021.100056 |
Ejemplares similares
-
COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy
por: Vitiello, Antonio, et al.
Publicado: (2020) -
Worldwide Recommendations and Therapies for Multiple Sclerosis: Are They Safe in the COVID-19 Pandemic Period?
por: Ferrara, Francesco, et al.
Publicado: (2020) -
The Central Role of Clinical Nutrition in COVID-19 Patients During and After Hospitalization in Intensive Care Unit
por: Ferrara, Francesco, et al.
Publicado: (2020) -
Antidiabetes Agents against Sars-Cov-2 Infection
por: Vitiello, Antonio, et al.
Publicado: (2020) -
Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19
por: Rabie, Amgad M.
Publicado: (2021)